News & analysis
Times are shown in GMT+2, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of innovative therapies to restore, treat and prevent hearing loss. The company's product is in Phase 2 clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies.Sensorion SA develops therapies dedicated to the treatment of vestibular and cochlear pathologies. Its product pipeline includes SENS-111, which is a treatment against acute dizziness.
Latest ALSEN News